Showing results (1311-1320 of 2,738) with videos related to

Sort By:
Pageof 274
Pharmacogenomics|July 31, 2012
Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Elisa Giovannetti, Francesca Toffalorio, Tommaso De Pas, et al.
Pharmacogenomics|July 31, 2012
Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failureJaap Fransen, Wouter M Kooloos, Judith A M Wessels, et al.
Pharmacogenomics|July 26, 2022
Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxelDaniel Herrero Rivera, Carmen Garrigós Vacas, Laura Marcos Kovandzic, et al.
Pharmacogenomics|September 13, 2018
Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional studyTheresa R Tonozzi, Glenn D Braunstein, Anja Kammesheidt, et al.
Pharmacogenomics|September 28, 2021
Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patientsZhenwei Jiang, Nan Hu
Pharmacogenomics|September 1, 2018
Letter to the EditorSelma Jm Eikelenboom-Schieveld, James C Fogleman
Pharmacogenomics|April 28, 2018
Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapyThomas O Bergmeijer, Gerrit Ja Vos, Daniël Mf Claassens, et al.
Pharmacogenomics|December 19, 2009
TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancerUte Warnecke-Eberz, Ralf Metzger, Elfriede Bollschweiler, et al.
Pharmacogenomics|December 19, 2009
Pathology practice and pharmacogenomicsRonald Ja Trent
Pharmacogenomics|April 16, 2019
Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotypeAntigoni Chaidaroglou, Theoni Kanellopoulou, George Panopoulos, et al.
Pageof 274